• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

11.93 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
July 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
July 08, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 07, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
July 06, 2026
From The Schall Law Firm
Via Business Wire
News headline image
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
June 26, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 15, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
May 13, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
May 11, 2026
From Omeros Corporation
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
April 16, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
March 31, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
March 26, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
March 21, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
February 17, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces First Commercial Sales of YARTEMLEA®
January 27, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
December 26, 2025
From Omeros Corporation
Via Business Wire
News headline image
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
December 24, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
December 01, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Third Quarter 2025 Financial Results
November 13, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
November 11, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
October 16, 2025
From Omeros Corporation
Via Business Wire
News headline image
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)
October 15, 2025
Via AB Newswire
Topics Artificial Intelligence Cannabis
News headline image
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
September 02, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Second Quarter 2025 Financial Results
August 14, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
August 11, 2025
From Omeros Corporation
Via Business Wire
InvestorNewsBreaks – D. Boral Capital LLC Acts as Exclusive Placement Agent for $22 Million Omeros (NASDAQ: OMER) Offering
August 01, 2025
Via Investor Brand Network
News headline image
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
July 31, 2025
Via ACCESS Newswire
News headline image
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
July 25, 2025
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap